new
world
arenaviru
viru
junv
caus
agent
argentin
hemorrhag
fever
lethal
human
infecti
diseas
adult
laboratori
mice
gener
resist
peripher
infect
junv
mechan
underli
mous
resist
junv
infect
larg
unknown
report
interferon
receptor
knockout
mice
succumb
junv
infect
indic
critic
role
interferon
restrict
junv
infect
mice
report
pathogen
vaccin
strain
junv
highli
sensit
interferon
murin
primari
cell
treatment
low
concentr
interferon
abrog
viral
np
protein
express
murin
cell
replic
junv
enhanc
defici
cell
addit
vaccin
strain
junv
display
impair
growth
primari
murin
cell
data
suggest
direct
potent
role
host
interferon
respons
restrict
junv
replic
mice
defect
viral
growth
vaccin
junv
might
also
partial
explain
attenu
mice
arenavirus
envelop
rna
virus
biseg
negativesens
genom
rna
base
antigen
phylogeni
geograph
distribut
divid
old
world
lassalymphocyt
choriomening
complex
arenavirus
new
world
tacarib
complex
arenavirus
recent
studi
identifi
sever
snakeborn
arenavirus
highli
diverg
known
arenavirus
lymphocyt
choriomening
viru
lcmv
old
world
ow
arenavirus
prototyp
arenaviru
new
world
nw
arenavirus
classifi
clade
b
c
nw
arenavirus
arenavirus
often
chronic
infect
natur
rodent
host
infect
human
mostli
acut
occur
probabl
mucos
exposur
aerosol
direct
contact
abrad
skin
infecti
materi
arenavirida
famili
includ
sever
import
human
pathogen
ow
lassa
viru
lasv
caus
agent
lassa
fever
major
public
health
concern
western
africa
sever
clade
b
nw
arenavirus
includ
viru
junv
machupo
viru
macv
guanarito
viru
gtov
sabia
viru
sabv
chapar
viru
chav
caus
human
hemorrhag
fever
diseas
south
america
junv
caus
agent
argentin
hemorrhag
fever
highli
infecti
human
diseas
case
fatal
meanwhil
junv
could
induc
lethal
transient
persist
infect
natur
rodent
host
calomi
musculinu
field
laboratori
studi
demonstr
junv
infect
primari
natur
rodent
host
larg
horizont
transmiss
close
contact
rodent
undergo
persist
infect
could
shed
larg
amount
viru
saliva
urin
junv
classifi
select
agent
center
diseas
control
prevent
unit
state
research
work
util
infecti
junv
requir
highcontain
biosafeti
level
facil
usa
live
attenu
vaccin
candid
develop
collabor
effort
us
armi
medic
research
institut
infecti
diseas
usamriid
argentin
ministri
health
social
action
origin
human
pathogen
xj
strain
serial
passag
guinea
pig
mous
brain
result
strain
attenu
guinea
pig
human
young
mice
infect
intracrani
addit
serial
passag
cell
viru
eventu
becam
attenu
young
mice
select
final
candid
vaccin
stock
adult
laboratori
mice
older
gener
resist
peripher
infect
junv
suckl
mice
vulner
lethal
viru
challeng
intracrani
mainli
develop
neurotrop
immunopatholog
diseas
distinct
symptom
observ
patient
experiment
infect
nonhuman
primat
guinea
pig
mechan
underli
mous
resist
junv
infect
larg
unknown
previous
report
mice
lack
type
type
ii
interferon
ifn
receptor
succumb
lethal
junv
infect
provid
novel
model
recapitul
symptom
found
ahf
patient
result
demonstr
critic
role
ifn
pathway
restrict
junv
infect
mice
prompt
us
explor
whether
ifn
could
directli
inhibit
junv
replic
murin
cell
studi
provid
evid
show
pathogen
vaccin
strain
junv
highli
sensit
interferon
treatment
murin
primari
cell
multipl
junv
enhanc
defici
cell
addit
vaccin
strain
junv
display
impair
growth
murin
primari
cell
could
partial
explain
attenu
viru
pathogen
strain
romero
junv
obtain
dr
thoma
g
ksiazek
center
diseas
control
prevent
atlanta
ga
vaccin
strain
candid
junv
vesicular
stomat
viru
provid
dr
robert
tesh
world
refer
center
emerg
virus
arbovirus
wrceva
univers
texa
medic
branch
galveston
tx
viru
stock
propag
vero
cell
american
tissu
cultur
collect
manassa
va
follow
filtrat
filter
mm
pore
size
remov
cell
debri
purif
ultra
k
filter
devic
ultralcel
k
molecular
weight
cutoff
amicon
millipor
human
lung
epitheli
cell
obtain
atcc
primari
mous
embryon
fibroblast
cell
deriv
wild
type
mice
knockout
mice
provid
dr
michael
diamond
washington
univers
work
pathogen
romero
strain
junv
perform
univers
texa
medic
branch
facil
galveston
nation
laboratori
accord
institut
health
safeti
guidelin
feder
regul
describ
previous
cell
seed
plate
h
treat
variou
concentr
human
mous
ifnb
pbl
indic
experi
cell
infect
candid
junv
moi
pfucel
ifn
supplement
viru
infect
protein
lysat
prepar
laemmli
sampl
buffer
day
pi
mef
cell
cell
vero
cell
day
pi
protein
sampl
resolv
sdspage
gel
transfer
pvdf
membran
use
mini
transblot
electrophoret
transfer
cell
apparatu
biorad
ca
membran
incub
primari
antibodi
overnight
appropri
secondari
antibodi
h
room
temperatur
protein
visual
ecl
western
blot
detect
reagent
ge
nj
accord
manufactur
instruct
viral
np
protein
detect
monoclon
mous
antijunv
np
antibodi
bei
equal
load
sampl
confirm
immunoblot
membran
antibodi
bactin
santa
cruz
secondari
antibodi
hrpconjug
goat
antimous
igg
jackson
immunolog
hrpconjug
donkey
antigoat
igg
santa
cruz
use
wildtyp
mef
cell
knockout
mef
cell
infect
romero
candid
virus
moi
supernat
infect
cell
harvest
daili
subject
plaqu
assay
describ
previous
statist
analysi
viru
growth
kinet
perform
two
way
anova
test
understand
ifn
direct
impact
junv
infect
character
effect
ifn
treatment
junv
multipl
primari
murin
embryon
fibroblast
cell
mef
deriv
mice
vero
cell
human
lung
epitheli
cell
mef
cell
treat
mous
ifnb
u
ml
hr
viru
infect
meanwhil
vero
cell
cell
treat
human
ifna
ifnb
ifnc
hr
infect
uml
fig
cell
infect
pathogen
romero
strain
vaccin
strain
candid
junv
multipl
infect
moi
pfucel
hr
post
infect
p
viru
titer
tissu
cultur
supernat
determin
plaqu
assay
also
includ
ifnsensit
vsv
control
result
show
ifnb
mediat
potent
antivir
effect
romero
candid
junv
infect
mef
cell
fig
notabl
low
dose
murin
ifnb
treatment
uml
result
drastic
decreas
viru
titer
candid
romero
junv
meanwhil
titer
vsv
reduc
u
ml
fig
multipl
candid
complet
abolish
mef
cell
treat
uml
ifnb
new
world
arenaviru
viru
junv
caus
agent
lethal
human
infecti
diseas
argentin
hemorrhag
fever
laboratori
mice
use
model
studi
mani
viral
diseas
howev
adult
laboratori
mice
gener
resist
junv
infect
interferon
earli
immun
regulatori
molecul
induc
potent
antivir
statu
host
cell
activ
host
immun
cell
counteract
viru
infect
activ
interferon
reli
cell
surfac
receptor
previous
report
mutant
mice
defect
interferon
receptor
succumb
challeng
junv
highlight
critic
role
interferon
restrict
junv
infect
mice
studi
basi
mous
resist
junv
infect
report
replic
pathogen
junv
vaccin
strain
highli
sensit
type
ifn
treatment
mous
cell
howev
strain
replic
effici
africa
green
monkeyderiv
vero
cell
human
cell
treat
high
dose
interferon
addit
vaccin
strain
replic
less
effici
mous
cell
compar
pathogen
strain
might
partial
explain
attenu
mice
new
find
help
better
understand
junvhost
interact
multipl
romero
viru
abolish
uml
fig
demonstr
high
sensit
junv
ifnmedi
antivir
effect
murin
cell
comparison
viru
titer
ifnsensit
lcmv
strain
decreas
approxim
treat
uml
murin
ifnab
murin
cell
ifnab
gene
defect
vero
cell
titer
junv
reduc
less
treat
high
concentr
human
ifna
b
c
uml
fig
consist
previou
studi
comparison
titer
vsv
remark
reduc
close
presenc
uml
human
ifnb
indic
rel
insensit
junv
strain
ifn
vero
cell
human
cell
treatment
uml
human
ifnb
suppress
viru
growth
candid
strain
romero
strain
respect
treatment
uml
human
ifnb
reduc
viru
titer
vsv
fig
result
show
strain
junv
rel
sensit
ifn
cell
vero
cell
less
suscept
ifn
ifnsensit
vsv
junv
growth
wt
mef
knockout
mef
seem
pathogen
romero
viru
replic
effici
vaccin
strain
candid
viru
wildtyp
mef
cell
fig
character
junv
growth
primari
mef
cell
moi
found
romero
viru
inde
multipli
significantli
greater
candid
viru
fig
two
way
anova
test
peak
titer
romero
viru
pfuml
candid
viru
pfuml
dpi
fig
junv
growth
examin
doubl
knockout
ko
mef
cell
moi
ifn
respons
larg
abrog
strain
show
enhanc
growth
ko
mef
cell
fig
romero
viru
replic
effici
vaccin
candid
viru
two
way
anova
test
peak
titer
romero
viru
pfuml
candid
viru
pfuml
dpi
differ
larg
compar
wildtyp
mef
fig
impli
impair
growth
candid
viru
less
like
associ
host
ifn
respons
like
due
intrins
growth
defici
primari
mef
cell
examin
junv
growth
mef
cell
lower
moi
moi
condit
mimick
viru
infect
vivo
fig
expect
romero
viru
grew
lower
peak
titer
cell
line
moi
next
studi
effect
ifn
viral
replic
understand
mechan
ifninduc
antiviru
activ
mef
cell
pretreat
murin
ifnb
uml
follow
infect
candid
junv
moi
data
clearli
show
treatment
uml
ifnb
almost
abolish
viral
np
protein
express
day
pi
fig
consist
viru
titrat
result
fig
np
protein
one
earli
viral
gene
product
express
viru
infect
result
suggest
ifn
probabl
target
earli
step
viru
infect
viru
entri
disassembl
earli
stage
viral
rna
replicationtranscript
mous
cell
cell
np
protein
express
inhibit
presenc
uml
human
ifnb
fig
consist
viru
titrat
data
fig
vero
cell
synthesi
np
protein
moder
suppress
fig
uml
human
ifnb
treatment
agreement
rel
resist
junv
ifn
treatment
cell
line
fig
overal
studi
reveal
high
sensit
junv
ifn
well
attenu
growth
candid
viru
primari
murin
cell
treatment
uml
ifnb
result
drastic
decreas
junv
titer
reduct
candid
romero
similar
inhibitori
effect
ifn
ifnsensit
vsv
fig
express
np
protein
abolish
presenc
exogen
uml
ifnb
candid
junv
murin
cell
moi
result
also
suggest
earli
stage
viru
replic
effici
suppress
ifn
murin
cell
known
exampl
ifninduc
gene
product
could
inhibit
viru
replic
earli
life
cycl
includ
mxa
inhibit
viral
nucleocapsid
shuttl
primari
transcript
influenza
viru
hcv
vsv
ifitm
inhibit
entri
influenza
viru
sar
coronaviru
west
nile
viru
complex
block
replic
certain
strain
wnv
venezuelan
equin
enceph
viru
target
viral
rna
either
lack
cap
structur
contain
triphosph
group
futur
studi
requir
identifi
step
viru
replic
block
ifn
treatment
studi
help
us
better
understand
junvhost
interact
also
facilit
design
antivir
strategi
interestingli
ifnsensit
lcmv
strain
armstrong
strain
treatment
higher
dose
murin
ifnab
uml
lead
reduct
viru
titer
murin
cell
capac
lcmv
strain
establish
persist
infect
adult
immunocompet
mice
also
correl
rel
resist
ifnab
ifnc
lassa
viru
treatment
high
concentr
human
ifna
uml
lead
approxim
reduct
viru
titer
human
cell
differ
experiment
condit
difficult
directli
compar
ifn
sensit
junv
mef
cell
result
aforement
studi
lcmv
lasv
howev
junv
appar
highli
sensit
ifn
murin
cell
could
least
partial
explain
mous
resist
junv
discuss
sinc
human
pathogen
vaccin
strain
junv
highli
suscept
ifn
murin
cell
identifi
studi
correl
could
establish
pathogen
junv
human
ifn
sensit
murin
cell
rel
resist
ifn
vero
cell
junv
suscept
ifn
cell
base
twostep
positivefeedback
loop
model
ifn
product
ifnb
produc
upon
viru
infect
first
step
secret
induc
express
next
stage
activ
stimul
express
ifn
allow
cell
mount
full
scale
antivir
respons
accordingli
possibl
exogen
ifnb
could
induc
synthesi
variou
subtyp
endogen
ifn
ifnproduct
compet
cell
result
robust
sustain
antivir
respons
vero
cell
due
defect
ifnb
ifna
gene
ifnmedi
antivir
respons
could
less
potent
cell
high
sensit
junv
ifn
murin
cell
might
explain
part
requir
intact
ifn
pathway
adult
mice
resist
junv
macrophag
known
one
initi
target
junv
infect
vivo
mous
macrophag
found
produc
ifn
cytokin
respons
infect
candid
viru
presum
pathogen
junv
result
host
recognit
viral
glycoprotein
protein
manner
consid
high
ifn
sensit
junv
murin
cell
identifi
herein
possibl
product
viral
infect
might
suppress
directli
ifninduc
antivir
gene
product
macrophag
cell
moreov
induc
ifn
cytokin
could
also
activ
differ
immun
cell
promot
junv
clearanc
vivo
host
barrier
could
detriment
junv
dissemin
mice
initi
stage
viral
infect
might
eventu
render
adult
mice
resist
junv
absenc
function
ifn
pathway
romero
junv
abl
establish
success
viru
infect
becom
pathogen
mice
role
ifn
respons
junv
pathogenesi
still
well
understood
high
level
ifna
detect
serum
sampl
argentin
hemorrhag
fever
ahf
patient
associ
sever
lethal
diseas
outcom
ifn
link
clinic
symptom
includ
thrombocytopenia
natur
rodent
host
role
ifn
junv
pathogenesi
persist
infect
remain
unclear
larg
due
lack
laboratori
inbr
anim
although
mous
natur
host
junv
result
murin
cell
provid
insight
basi
candid
viru
attenu
candid
mutat
lead
viru
attenu
human
guinea
pig
establish
ancestor
xj
strain
establish
passag
human
pathogen
xj
strain
mous
brain
attenu
human
guinea
pig
still
virul
suckl
mice
introduc
intracrani
vaccin
candid
strain
establish
addit
passag
xj
strain
cell
attenu
candid
well
character
mous
model
recent
genet
studi
viral
gpc
glycoprotein
found
main
determin
junv
virul
mice
among
total
six
amino
acid
chang
candid
viru
sequenc
compar
strain
singl
substitut
transmembran
region
gpc
suffici
junv
attenu
suckl
mice
howev
mechan
attenu
possibl
effect
accumul
mutat
viru
replic
murin
system
establish
demonstr
impair
growth
candid
viru
primari
murin
cell
evid
moi
defect
might
relat
increas
depend
candid
glycoprotein
human
transferrin
receptor
viru
entri
compromis
effici
candid
np
l
protein
support
viral
rna
transcriptionrepl
mechan
remain
identifi
futur
studi
system
character
effect
candid
mutat
viru
replic
murin
system
warrant
util
junv
revers
genet
system
impair
viru
growth
murin
cell
candid
strain
biolog
relev
attenu
could
least
part
explain
inabl
candid
viru
caus
dissemin
infect
mice
lack
function
ifn
system
unpublish
observ
